Abstract: In The present invention relates in a first aspect to the use of influenza virus defective interfering particles in the prophylactic or therapeutic treatment of coronaviridae infection. In particular, it has been recognized that defective interfering particles of influenza A have beneficial effects in the treatment of SARS coronavirus infection, in particular, SARS-CoV-2 infection. Further, the present invention relates to a pharmaceutical composition for use in treating coronaviridae infection, in particular SARS-CoV-2. In a further aspect, methods for the prophylactic or therapeutic treatments of coronaviridae based on the administration of DIFs are disclosed.

Abstract: In a first aspect, the present invention relates to a method for the purification of virus compositions as well as biological macromolecular compounds in a sample comprising mixing the sample with osmolytes, like non-ionic organic polymers and contacting the mixed sample with a hydrophilic membrane, optionally washing the membrane, and eluting the virus preparations or biological macromolecular components from the membrane with an eluting solution containing reduced amounts or no osmolytes, like non-ionic organic polymer. Moreover, virus compositions and biological macromolecular components obtainable with the method according to the present invention are provided as well as the use of the method according to the present invention for purification of virus compositions including whole virus particles and virus-like particles or biological macromolecular components.

Abstract: The present invention relates in a first aspect to a plug flow tubular bioreactor having an integral or multi-part tube adapted for cultivation, and, optionally, infection, viral transduction, or transfection of eukaryotic cells. In a further aspect, the present invention relates to a plug flow tubular bioreactor system comprising the plug flow tubular bioreactor according to the present invention. Further, the present invention relates to a method for preparing virus particles, vectors, cells or other molecules including toxic molecules using the plug flow tubular bioreactor or the system according to the present invention. Finally, the present invention relates to the use of a plug flow tubular bioreactor for the preparation of virus particles, vectors including viral vectors, cells including modified cells or other molecules including toxic molecules.

Abstract: The present invention relates in a first aspect to a plug flow tubular bioreactor having an integral or multi-part tube adapted for cultivation, and, optionally, infection, viral transduction, or transfection of eukaryotic cells. In a further aspect, the present invention relates to a plug flow tubular bioreactor system comprising the plug flow tubular bioreactor according to the present invention. Further, the present invention relates to a method for preparing virus particles, vectors, cells or other molecules including toxic molecules using the plug flow tubular bioreactor or the system according to the present invention. Finally, the present invention relates to the use of a plug flow tubular bioreactor for the preparation of virus particles, vectors including viral vectors, cells including modified cells or other molecules including toxic molecules.

Abstract: In a first aspect, the present invention relates to an isolated nucleic acid molecule, in particular, an RNA molecule containing particular substitutions. In a further aspect, the present invention relates to a composition comprising the same as well as virus-like particle, viral vector or virus particle containing the nucleic acid molecule according to the present invention. The virus-like particle, the viral vector or the virus particle is suitable for use as a medicament in particular for treating viral infection. Further, a pharmaceutical composition is provided in particular suitable for use as a pharmaceutical prophylactic vaccine containing the virus-like particle, viral vector or the virus particle or the nucleic acid molecule according to the present invention.

Abstract: The present invention relates to improved (simplified/easier, more robust and more reproducible) methods for identification of carbohydrates compositions, e.g. out of complex carbohydrate mixtures, as well as the determination of carbohydrate mixture composition patterns (e.g.: of glycosylation patterns) based on advanced internal standards to determine precise and highly reproducible migration and retention time indices using novel fluorescent dyes in combination with high performance separation technologies, like capillary (gel) electrophoresis (C(G)E) or (ultra)high performance liquid chromatography (U)HPLC with a highly sensitive detection like (laser induced) fluorescence detection.

Abstract: In a first aspect, the present invention relates to an isolated nucleic acid molecule, in particular, an RNA molecule containing particular substitutions. In a further aspect, the present invention relates to a composition comprising the same as well as virus-like particle, viral vector or virus particle containing the nucleic acid molecule according to the present invention. The virus-like particle, the viral vector or the virus particle is suitable for use as a medicament in particular for treating viral infection. Further, a pharmaceutical composition is provided in particular suitable for use as a pharmaceutical prophylactic vaccine containing the virus-like particle, viral vector or the virus particle or the nucleic acid molecule according to the present invention.

Abstract: The present invention relates to methods for the identification of compounds in carbohydrate mixture compositions as well as the determination of carbohydrate mixture composition patterns, based on e.g. orthogonal cross determining migration time (indices) using capillary gel electrophoresis-laser induced fluorescence and identifying said carbohydrate components based on comparing said migration time (indices) with standard migration time (indices) from a database which data are preferably also orthogonal cross determined. In a further aspect, the present invention relates to a method for carbohydrate mixture composition pattern profiling, like glycosylation pattern profiling using capillary gel electrophoresis-laser induced fluorescence (CGE-LIF). In another aspect, the present invention refers to a system for an automated determination and/or identification of carbohydrates and/or carbohydrate mixture composition patterns (e.g.: glycosylation patterns).

Abstract: The present invention relates in a first aspect to a plug flow tubular bioreactor having an integral or multi-part tube adapted for cultivation, and, optionally, infection, viral transduction, or transfection of eukaryotic cells. In a further aspect, the present invention relates to a plug flow tubular bioreactor system comprising the plug flow tubular bioreactor according to the present invention. Further, the present invention relates to a method for preparing virus particles, vectors, cells or other molecules including toxic molecules using the plug flow tubular bioreactor or the system according to the present invention. Finally, the present invention relates to the use of a plug flow tubular bioreactor for the preparation of virus particles, vectors including viral vectors, cells including modified cells or other molecules including toxic molecules.

Abstract: In a first aspect, the present invention relates to a method for the purification of virus compositions as well as biological macromolecular compounds in a sample comprising mixing the sample with osmolytes, like non-ionic organic polymers and contacting the mixed sample with a hydrophilic membrane, optionally washing the membrane,and eluting the virus preparations or biological macromolecular components from the membrane with an eluting solution containing reduced amounts or no osmolytes, like non-ionic organic polymer. Moreover, virus compositions and biological macromolecular components obtainable with the method according to the present invention are provided as well as the use of the method according to the present invention for purification of virus compositions including whole virus particles and virus-like particles or biological macromolecular components.

Abstract: The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.

Abstract: The present invention relates to methods for purification of Vaccinia viruses (VV) and/ or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.

Abstract: The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.

Abstract: The present invention relates to methods for the identification of compounds in carbohydrate mixture compositions as well as the determination of carbohydrate mixture composition patterns, based on e.g. orthogonal cross determining migration time (indices) using capillary gel electrophoresis-laser induced fluorescence and identifying said carbohydrate components based on comparing said migration time (indices) with standard migration time (indices) from a database which data are preferably also orthogonal cross determined. In a further aspect, the present invention relates to a method for carbohydrate mixture composition pattern profiling, like glycosylation pattern profiling using capillary gel electrophoresis-laser induced fluorescence (CGE-LIF). In another aspect, the present invention refers to a system for an automated determination and/or identification of carbohydrates and/or carbohydrate mixture composition patterns (e.g.: glycosylation patterns).

Abstract: The present invention relates to methods for the identification of compounds in carbohydrate mixture compositions as well as the determination of carbohydrate mixture composition patterns, based on e.g. orthogonal cross determining migration time (indices) using capillary gel electrophoresis-laser induced fluorescence and identifying said carbohydrate components based on comparing said migration time (indices) with standard migration time (indices) from a database which data are preferably also orthogonal cross determined. In a further aspect, the present invention relates to a method for carbohydrate mixture composition pattern profiling, like glycosylation pattern profiling using capillary gel electrophoresis-laser induced fluorescence (CGE-LIF). In another aspect, the present invention refers to a system for an automated determination and/or identification of carbohydrates and/or carbohydrate mixture composition patterns (e.g.: glycosylation patterns).

Abstract: The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.

Abstract: The present invention relates to methods for the preparation of functionalized sulfated cellulose membranes. In particular, the present invention relates to the preparation of sulfated cellulose membranes under specific reaction conditions allowing to provide a sulfated cellulose membrane useful for pseudo-affinity purification. In another aspect, the present invention relates to the sulfated cellulose membrane itself as well as its use for isolation of proteinaceous compositions. Finally, the present invention provides a method for isolating whole virus, virus proteins or heparin binding molecules comprising the step of affinity purification using the sulfated cellulose membrane according to the present invention.

Abstract: The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.

Abstract: The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.

Abstract: The invention relates to a device and a method for taking liquid or gaseous samples from containers and/or tubes that are filled with a medium, in particular from fermenters, by means of negative pressure, wherein an element which acts as a non-return valve is arranged within a sample probe as an inlet for the sample that is to be taken, and a supply line which is able to convey gas and a discharge line which is able to discharge sample are arranged on a common side of the element.